🎉 M&A multiples are live!
Check it out!

Chong Kun Dang Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Chong Kun Dang Pharma and similar public comparables like Vivoryon Therapeutics, Galapagos, and Julphar.

Chong Kun Dang Pharma Overview

About Chong Kun Dang Pharma

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).


Founded

1941

HQ

South Korea
Employees

n/a

Financials

LTM Revenue $1.1B

LTM EBITDA $86.7M

EV

$621M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Chong Kun Dang Pharma Financials

Chong Kun Dang Pharma has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $86.7M.

In the most recent fiscal year, Chong Kun Dang Pharma achieved revenue of $1.1B and an EBITDA of $102M.

Chong Kun Dang Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Chong Kun Dang Pharma valuation multiples based on analyst estimates

Chong Kun Dang Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.1B $1.1B XXX XXX XXX
Gross Profit $370M $451M XXX XXX XXX
Gross Margin 33% 42% XXX XXX XXX
EBITDA $196M $102M XXX XXX XXX
EBITDA Margin 17% 9% XXX XXX XXX
Net Profit $55.2M $145M XXX XXX XXX
Net Margin 5% 13% XXX XXX XXX
Net Debt $79.5M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Chong Kun Dang Pharma Stock Performance

As of April 15, 2025, Chong Kun Dang Pharma's stock price is KRW 77800 (or $53).

Chong Kun Dang Pharma has current market cap of KRW 1.03T (or $698M), and EV of KRW 911B (or $621M).

See Chong Kun Dang Pharma trading valuation data

Chong Kun Dang Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$621M $698M XXX XXX XXX XXX $5.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Chong Kun Dang Pharma Valuation Multiples

As of April 15, 2025, Chong Kun Dang Pharma has market cap of $698M and EV of $621M.

Chong Kun Dang Pharma's trades at 0.6x LTM EV/Revenue multiple, and 7.2x LTM EBITDA.

Analysts estimate Chong Kun Dang Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Chong Kun Dang Pharma and 10K+ public comps

Chong Kun Dang Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $621M XXX XXX XXX
EV/Revenue 0.6x XXX XXX XXX
EV/EBITDA 6.1x XXX XXX XXX
P/E 9.4x XXX XXX XXX
P/E/Growth -1.2x XXX XXX XXX
EV/FCF -502.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chong Kun Dang Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Chong Kun Dang Pharma Valuation Multiples

Chong Kun Dang Pharma's NTM/LTM revenue growth is 7%

Chong Kun Dang Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Chong Kun Dang Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Chong Kun Dang Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Chong Kun Dang Pharma and other 10K+ public comps

Chong Kun Dang Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -5% XXX XXX XXX XXX
EBITDA Margin 9% XXX XXX XXX XXX
EBITDA Growth -48% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 16% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 7% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 9% XXX XXX XXX XXX
Opex to Revenue 27% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Chong Kun Dang Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Chong Kun Dang Pharma M&A and Investment Activity

Chong Kun Dang Pharma acquired  XXX companies to date.

Last acquisition by Chong Kun Dang Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Chong Kun Dang Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Chong Kun Dang Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Chong Kun Dang Pharma

When was Chong Kun Dang Pharma founded? Chong Kun Dang Pharma was founded in 1941.
Where is Chong Kun Dang Pharma headquartered? Chong Kun Dang Pharma is headquartered in South Korea.
Who is the CEO of Chong Kun Dang Pharma? Chong Kun Dang Pharma's CEO is Mr. Young-joo Kim.
Is Chong Kun Dang Pharma publicy listed? Yes, Chong Kun Dang Pharma is a public company listed on KRX.
What is the stock symbol of Chong Kun Dang Pharma? Chong Kun Dang Pharma trades under 185750 ticker.
When did Chong Kun Dang Pharma go public? Chong Kun Dang Pharma went public in 2013.
Who are competitors of Chong Kun Dang Pharma? Similar companies to Chong Kun Dang Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Chong Kun Dang Pharma? Chong Kun Dang Pharma's current market cap is $698M
What is the current revenue of Chong Kun Dang Pharma? Chong Kun Dang Pharma's last 12-month revenue is $1.1B.
What is the current EBITDA of Chong Kun Dang Pharma? Chong Kun Dang Pharma's last 12-month EBITDA is $86.7M.
What is the current EV/Revenue multiple of Chong Kun Dang Pharma? Current revenue multiple of Chong Kun Dang Pharma is 0.6x.
What is the current EV/EBITDA multiple of Chong Kun Dang Pharma? Current EBITDA multiple of Chong Kun Dang Pharma is 7.2x.
What is the current revenue growth of Chong Kun Dang Pharma? Chong Kun Dang Pharma revenue growth between 2023 and 2024 was -5%.
Is Chong Kun Dang Pharma profitable? Yes, Chong Kun Dang Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.